View Older Stories View More Recent Stories

May 29, 2020 08:18AM Myovant Sciences (MYOV) Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in NEJM
May 29, 2020 08:09AM Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New Engl
May 29, 2020 08:09AM Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New Engl
May 18, 2020 04:05PM Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2020
May 14, 2020 08:30AM Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
May 14, 2020 08:30AM Myovant Sciences to Present New Data on Relugolix in Prostate Cancer at American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
Apr 27, 2020 08:32AM Myovant Sciences (MYOV) Reports Publication of of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies
Apr 27, 2020 08:30AM Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
Apr 27, 2020 08:30AM Myovant Sciences Announces Publication of Abstracts Detailing Additional Efficacy and Safety Findings from Phase 3 LIBERTY Studies in Uterine Fibroids in Obstetrics & Gynecology
Apr 22, 2020 07:31AM Myovant Sciences (MYOV) Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study Met Co-Primary Endpoints
Apr 22, 2020 07:30AM Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
Apr 22, 2020 07:30AM Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
Apr 21, 2020 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in
Apr 21, 2020 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Wednesday, April 22 to Discuss Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in
Apr 21, 2020 08:37AM Myovant Sciences (MYOV) Submits NDA to FDA for Once-Daily, Oral Relugolix for Treatment of Men with Advanced Prostate Cancer
Apr 21, 2020 08:30AM Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Apr 21, 2020 08:30AM Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
Apr 14, 2020 08:30AM Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
Apr 14, 2020 08:30AM Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health
Mar 31, 2020 08:43AM Myovant Sciences (MYOV) and Gedeon Richter Enter Pact to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Mar 31, 2020 02:00AM Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Mar 31, 2020 02:00AM Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
Mar 10, 2020 08:30AM Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
Mar 10, 2020 08:30AM Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020
Mar 9, 2020 08:35AM Myovant Sciences (MYOV) Submits MAA to European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar 9, 2020 08:30AM Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Mar 9, 2020 08:30AM Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Feb 25, 2020 08:30AM Myovant Sciences to Present at Upcoming March Investor Conferences
Feb 25, 2020 08:30AM Myovant Sciences to Present at Upcoming March Investor Conferences
Feb 10, 2020 08:30AM Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019
Feb 10, 2020 08:26AM Myovant Sciences (MYOV) Announces 88% One-Year RR in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 10, 2020 08:25AM Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Feb 10, 2020 08:25AM Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
Jan 6, 2020 08:30AM Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Jan 6, 2020 08:30AM Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 30, 2019 08:30AM Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Dec 30, 2019 08:30AM Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
Nov 25, 2019 04:05PM Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Nov 25, 2019 04:05PM Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
Nov 19, 2019 07:30AM Myovant Sciences (MYOV) Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
Nov 19, 2019 07:30AM Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
Nov 19, 2019 07:30AM Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
Nov 18, 2019 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Pro
Nov 18, 2019 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Pro
Nov 12, 2019 08:20AM Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019
Oct 31, 2019 09:20AM Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Oct 31, 2019 09:20AM Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
Oct 21, 2019 08:32AM Myovant Sciences (MYOV) Reports Complete Patient Recruitment for Ph. 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Oct 21, 2019 08:30AM Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
Oct 17, 2019 05:00AM Female Forward Together, a Cross-Sector Coalition, Announced to Advance Research, Education, and Action for Women’s Health
View More Recent Stories View Older Stories